Access Pharmaceuticals, Inc. is an emerging pharmaceutical company focused on the development and commercialization of proprietary products for the treatment and supportive care of cancer patients. Access has one approved product, two products in Phase development, and five preclinical development programs. The company s approved product is MuGard TM for the management of oral mucositis a common and debilitating side effect of many cancer therapies for which marketing authorization has been allowed by the FDA. Access ProLindac TM , a polymer linked platinum cancer drug is in Phase clinical testing in cancer patients, as is Phenylbutyrate, a pleotropic agent which current evidence suggests acts as both an HDAC inhibitor and a differentiating agent. The Company s preclinical development programs include Angiolix, a humanized monoclonal antibody which acts as an anti angiogenesis factor and is potentially targeted to a number of tumor types, including breast and ovarian Prodrax, a non toxic prodrug which is activated in the hypoxic zones of solid tumors to kill tumor cells Alchemix, a chemotherapeutic agent that combines two modes of action to overcome drug resistance, and oral insulin, which utilizes the company s Cobalamin TM oral drug delivery technology.
Quote | Abeona Therapeutics Inc. (NASDAQ:ABEO)
Last: | $4.40 |
---|---|
Change Percent: | -0.88% |
Open: | $4.6 |
Close: | $4.40 |
High: | $4.6199 |
Low: | $4.325 |
Volume: | 455,091 |
Last Trade Date Time: | 05/08/2024 03:00:00 am |
News | Abeona Therapeutics Inc. (NASDAQ:ABEO)
2024-05-03 08:14:19 ET More on Abeona Therapeutics Buying The Dip In Abeona Therapeutics After The Recent Manufacturing-Related CRL Abeona Therapeutics Tanks On CRL From The FDA, But All Hope Is Not Lost Read the full article on Seeking Alpha For further deta...
CLEVELAND, May 03, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) (“Abeona” or the “Company”) today announced the pricing of an underwritten offering of 12,285,056 shares of its common stock and, in lieu of common stock, pre-funded warrants to purchas...
Message Board Posts | Abeona Therapeutics Inc. (NASDAQ:ABEO)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $ABEO News Article - Abeona Therapeutics Announces Update on AAV Ophthalmology Program | whytestocks | investorshangout | 03/14/2023 12:21:07 PM |
whytestocks: $ABEO News Article - PXMD, GETY: The Top 5 Short Squeeze Stocks to Watch This Week | whytestocks | investorshangout | 11/21/2022 6:35:49 PM |
You gots me CONFUSED, Young Lady!! YES, I | Invest-in-America | investorshub | 10/12/2022 2:34:13 PM |
you already posted there silly, so i replied | gail | investorshub | 10/12/2022 2:26:24 PM |
O.K., I'll take a look at THAT one | Invest-in-America | investorshub | 10/12/2022 2:24:19 PM |
News, Short Squeeze, Breakout and More Instantly...
Abeona Therapeutics Inc. Company Name:
ABEO Stock Symbol:
NASDAQ Market:
Abeona Therapeutics Inc. Website:
CLEVELAND, May 03, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) (“Abeona” or the “Company”) today announced the pricing of an underwritten offering of 12,285,056 shares of its common stock and, in lieu of common stock, pre-funded warrants to purchas...
U.S. stocks traded higher toward the end of trading, with the S&P 500 gaining more than 1% on Tuesday. The Dow traded up 0.68% to 38,499.41 whi...
Shares of Nucor Corporation (NYSE:NUE) fell sharply during Tuesday's session after the company reported worse-than-expected quarterly financia...